{"url_path":"/sec/artv/8-k/2026-09-11/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-09-11","source_url":"https://www.sec.gov/Archives/edgar/data/1817241/0001193125-26-389308-index.html","accession_number":"0001193125-26-389308","cik":"0001817241","ticker":"ARTV","issuer_name":"Artiva Biotherapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1817241/0001193125-26-389308-index.html","primary_entity_key":"0001817241","primary_entity_name":"Artiva Biotherapeutics, Inc."},"word_count":207,"has_tables":true,"body_markdown":"Item 5.02\n\nDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.\n\n \n\n(e) On September 8, 2026, the Company held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders approved an amendment to the Company’s 2024 Equity Incentive Plan (the “2024 Plan” and the 2024 Plan, as amended, the “Amended 2024 Plan”) to, among other things, increase the number of shares of common stock authorized for issuance under the plan by 5,097,095 shares and to include in the calculation of the annual automatic share reserve increase, shares of common stock issuable upon the exercise of any pre-funded warrants. The Amended 2024 Plan was previously approved, subject to stockholder approval, by the Company’s Board on July 15, 2026. A summary of the principal features of the Amended 2024 Plan are set forth under the heading “Proposal No. 3―Approval of Amendment to the Company’s 2024 Equity Incentive Plan” contained in the Company’s definitive proxy statement on [Schedule 14A](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001817241/000119312526330563/artv-20260803.htm#proposal3), filed with the Securities and Exchange Commission on August 3, 2026 (the “2026 Proxy Statement”). The summary is qualified in its entirety by reference to the Amended 2024 Plan, filed as Exhibit 10.1 to this report."}